LeMaitre Vascular will announce its Q2 2026 financial results on August 4, followed by a conference call at 5 PM EDT.
Quiver AI Summary
LeMaitre Vascular, Inc. announced that it will release its second quarter 2026 financial results on August 4, 2026, after the market closes. A conference call to discuss these results, along with business highlights and the company outlook, is scheduled for 5:00 PM EDT that same day. Interested parties can register online for access to the live call and will receive dial-in instructions. An audio webcast of the call will also be available. LeMaitre Vascular specializes in devices, implants, and services for treating peripheral vascular disease, which affects over 200 million people globally, and focuses on meeting the needs of vascular surgeons. More information about the company can be found on its website.
Potential Positives
- Announcement of the upcoming release of second quarter 2026 financial results indicates transparency and commitment to shareholder communication.
- Scheduled conference call for in-depth discussion on financial results and company outlook can enhance investor confidence and engagement.
- The focus on a significant global health issue, peripheral vascular disease, highlights LeMaitre’s role in addressing a large market with critical medical needs.
Potential Negatives
- e
FAQ
When will LeMaitre Vascular announce its Q2 2026 financial results?
LeMaitre Vascular will announce its Q2 2026 financial results on August 4, 2026, after market close.
What time is the LeMaitre Vascular conference call?
The conference call will take place at 5:00 PM EDT on August 4, 2026.
How can I access the live conference call?
You can access the live conference call by registering online to receive dial-in information and a PIN.
Where can I listen to the audio webcast of the conference call?
The audio webcast can be accessed live or via replay at ir.lemaitre.com.
What does LeMaitre Vascular specialize in?
LeMaitre Vascular specializes in devices, implants, and services for treating peripheral vascular disease.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LMAT Insider Trading Activity
$LMAT insiders have traded $LMAT stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $LMAT stock by insiders over the last 6 months:
- GEORGE W LEMAITRE (Chairman and CEO) has made 0 purchases and 2 sales selling 205,930 shares for an estimated $22,043,375.
- DAVID B ROBERTS (President and Director) has made 0 purchases and 2 sales selling 11,775 shares for an estimated $1,260,543.
- TRENT G KAMKE (Senior V. P., Operations) has made 0 purchases and 2 sales selling 3,669 shares for an estimated $399,955.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$LMAT Revenue
$LMAT had revenues of $66.6M in Q1 2026. This is an increase of 11.16% from the same period in the prior year.
You can track LMAT financials on Quiver Quantitative's LMAT stock page.
You can access data on LMAT stock through the Quiver Quantitative API.
$LMAT Hedge Fund Activity
We have seen 165 institutional investors add shares of $LMAT stock to their portfolio, and 115 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DRIEHAUS CAPITAL MANAGEMENT LLC added 197,225 shares (+inf%) to their portfolio in Q1 2026, for an estimated $21,531,053
- FIFTH THIRD BANCORP added 151,227 shares (+1534.2%) to their portfolio in Q1 2026, for an estimated $16,509,451
- TWO SIGMA INVESTMENTS, LP added 138,670 shares (+96.8%) to their portfolio in Q1 2026, for an estimated $15,138,603
- CONGRESS ASSET MANAGEMENT CO added 129,177 shares (+15.5%) to their portfolio in Q2 2026, for an estimated $12,395,824
- BESSEMER GROUP INC added 128,033 shares (+292.3%) to their portfolio in Q1 2026, for an estimated $13,977,362
- SELECT EQUITY GROUP, L.P. added 100,470 shares (+inf%) to their portfolio in Q1 2026, for an estimated $10,968,309
- MARSHALL WACE, LLP added 82,992 shares (+172.1%) to their portfolio in Q1 2026, for an estimated $9,060,236
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$LMAT Price Targets
Multiple analysts have issued price targets for $LMAT recently. We have seen 4 analysts offer price targets for $LMAT in the last 6 months, with a median target of $118.5.
Here are some recent targets:
- Michael Petusky from Barrington Research set a target price of $120.0 on 06/03/2026
- Nathan Treybeck from Wells Fargo set a target price of $104.0 on 05/06/2026
- Daniel Stauder from Citizens set a target price of $127.0 on 05/06/2026
- Kyle Bauser from Roth Capital set a target price of $117.0 on 02/26/2026
Full Release
BURLINGTON, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2026 financial results on Tuesday, August 4, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.
Access to the live call is available by registering online here . All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay at ir.lemaitre.com .
About LeMaitre
LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.com.
LeMaitre and the LeMaitre logo are registered trademarks of LeMaitre Vascular, Inc.
